Clinical evaluation of Duraflo® II heparin treated extracorporeal circulation circuits (2nd version) The European working group on heparin coated extracorporeal circulation circuits

Objectives: To evaluate whether the application of heparin treated circuits for elective coronary artery surgery improves postoperative recovery, a European multicenter randomised clinical trial was carried out.Methods: In 11 European heart centers, 805 low-risk patients underwent cardiopulmonary bypass (CPB) with either an untreated circuit (n= 407) or an identical but heparin treated circuit (n= 398, Duraflo ® II).Results: Significant differences were found among participating centers with respect to patient characteristics, blood handling procedures and postoperative care.The use of heparin treated circuits revealed no overall changes in blood loss, blood use, time on ventilator, occurrence of adverse events, morbidity, mortality, and intensive care stay.These results did not change after adjustment for centers and (other) prognostic factors as analysed with logistic regression.In both groups no clinical or technical (patient or device related) side effects were reported.Because female gender and aortic